These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35723359)

  • 21. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
    Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
    Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.
    Feng F; Yehia L; Ni Y; Chang YS; Jhiang SM; Eng C
    Cancer Res; 2018 Nov; 78(21):6121-6133. PubMed ID: 30217930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
    Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
    Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells.
    Chai W; Ye F; Zeng L; Li Y; Yang L
    J Exp Clin Cancer Res; 2019 Jul; 38(1):325. PubMed ID: 31331356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The sodium iodide symporter: its pathophysiological and therapeutic implications.
    Spitzweg C; Morris JC
    Clin Endocrinol (Oxf); 2002 Nov; 57(5):559-74. PubMed ID: 12390328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.
    Kotlarek M; Kubiak A; Czetwertyńska M; Świerniak M; Gierlikowski W; Kolanowska M; Bakuła-Zalewska E; Jhiang SM; Jażdżewski K; Wójcicka A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas.
    Arturi F; Russo D; Giuffrida D; Schlumberger M; Filetti S
    Eur J Endocrinol; 2000 Nov; 143(5):623-7. PubMed ID: 11078986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
    Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
    Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
    J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
    Cai X; Wang R; Tan J; Meng Z; Li N
    Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation and tissue distribution of the human sodium iodide symporter gene.
    Ajjan RA; Kamaruddin NA; Crisp M; Watson PF; Ludgate M; Weetman AP
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):517-23. PubMed ID: 9876351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells.
    Faria M; Domingues R; Bugalho MJ; Matos P; Silva AL
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.
    Oh JM; Kalimuthu S; Gangadaran P; Baek SH; Zhu L; Lee HW; Rajendran RL; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
    Oncotarget; 2018 Jan; 9(6):7075-7087. PubMed ID: 29467951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells.
    Spitzweg C; Joba W; Morris JC; Heufelder AE
    Thyroid; 1999 Aug; 9(8):821-30. PubMed ID: 10482376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [β-catenin nuclear translocation represses thyroid cancer stem cells differentiating into cells with sodium-iodine symporter functional expression].
    Lan L; Deng W; Cui D; Chen HL; Huo LL; Zuo QY; Li W; Zhang GY; Luo Y
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1904-1910. PubMed ID: 31269588
    [No Abstract]   [Full Text] [Related]  

  • 37. The PDZ protein SCRIB regulates sodium/iodide symporter (NIS) expression at the basolateral plasma membrane.
    Martín M; Salleron L; Peyret V; Geysels RC; Darrouzet E; Lindenthal S; Bernal Barquero CE; Masini-Repiso AM; Pourcher T; Nicola JP
    FASEB J; 2021 Aug; 35(8):e21681. PubMed ID: 34196428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Nuclear translocation of β-catenin represses membrane localization of NIS in human thyroid cancer cells].
    Lan L; Deng W; Chen H; Huo L; Deng L; Zhang G; Luo Y
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(11):891-6. PubMed ID: 27045654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibiting β-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization.
    Lan L; Basourakos S; Cui D; Zuo X; Deng W; Huo L; Chen L; Zhang G; Deng L; Shi B; Luo Y
    Oncol Rep; 2017 Jan; 37(1):426-434. PubMed ID: 27840971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.